One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
Open Accesshttps://doi.org/10.1182/blood-2020-134437
Copy DOI
Export
Save
Share
Cite Journal: Blood |  Publication Date: Nov 5, 2020 |
 Citations: 4 |
Affiliation: The University of Texas MD Anderson Cancer Center, Medical University of Lodz, Dokuz Eylül University, Tel Aviv University, Hospital de Sant Pau, North Shore Hospital, St James's University Hospital, Norton Healthcare, Pharmacyclics (United States), AbbVie (United States), University of California, San Diego, Ospedale Niguarda Ca' Granda
Outcomes of First-Line Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and iLLUMINATE)
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
